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Background: Since hypothyroidism is a fairly common dysfunction, levothyroxine (L-T4) 
is one of the most prescribed medications. Approximately 70% of the administered L-T4 
dose is absorbed. The absorption process takes place in the small intestine. Some 
disorders of the digestive system and some medicines, supplements, and drinks cause 
L-T4 malabsorption, resulting in failure of serum TSH to be normal. Only rarely liver 
cirrhosis is mentioned as causing L-T4 malabsorption.
Case report: In this study, we report increased requirement of daily doses of l-thyroxine 
in two patients with the atrophic variant of Hashimoto’s thyroiditis and liver cirrhosis. In 
one patient, this increased requirement could have been contributed by the increased 
serum levels of the estrogen-dependent thyroxine-binding globulin (TBG), which is the 
major plasma carrier of thyroid hormones. In the other patient, we switched from tablet 
L-T4 to liquid L-T4 at the same daily dose. Normalization of TSH levels was achieved, 
but TSH increased again when she returned to tablet L-T4.
Conclusion: Liver cirrhosis can cause increased L-T4 requirements. In addition 
to impaired bile secretion, the mechanism could be increased serum TBG. A similar 
increased requirement of L-T4 is observed in other situations characterized by elevation 
of serum TBG. Because of better intestinal absorption, L-T4 oral liquid formulation is able 
to circumvent the increased need of L-T4 in these patients.
Keywords: liver cirrhosis, undertreated hypothyroidism, thyroxine malabsorption, liquid levothyroxine, thyroxine-
binding globulin
INtRoDUCtIoN
Hypothyroidism is a fairly common dysfunction and its incidence grows with age. Therefore levothy-
roxine (L-T4) is one of the most prescribed medications (1). Approximately 70% of the administered 
L-T4 dose is absorbed after L-T4 tablet dissolution in the acid intragastric environment. The absorp-
tion process takes place in the duodenum, jejunum, and ileum (2–4).
Several gastrointestinal disorders (gastritis, celiac disease, lactose intolerance, intestinal parasi-
tosis, and bariatric surgery) and various medicines, supplements, and drinks reduce the absorption 
of L-T4 (5–14). Recently, Lobasso et al. (15) reported a woman with systemic sclerosis in whom 
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dysmotility of distal esophagus caused L-T4 malabsorption. Also, 
a dysbiosis has been postulated to be involved in pharmacologic 
homeostasis of thyroxine (16, 17).
Among 210 subjects who were observed by one of us because 
of undertreated primary hypothyroidism in spite of adequate 
daily dose of L-T4, 27 (12.9%) had an increased need of L-T4 
(5). The gastrointestinal-related causes of increased need of L-T4 
were celiac disease (n = 3), Crohn’s enteritis (n = 1), co-ingestion 
of proton-pump inhibitors (PPIs, n = 6) alone or combined with 
other L-T4 sequestrants (ferrous salts or calcium salts). There are 
two disorders of the digestive system, liver cirrhosis, and diabetic 
diarrhea, which are rarely mentioned as the cause of an increase 
of L-T4 demand (18, 19). Chronic obstructive liver disease and 
pancreatic insufficiency are mentioned only in less recent reviews 
(20, 21). Textbooks and literature fail to mention that bile is 
important to maximize the intestinal absorption of L-T4 (22).
BaCKGRoUND
Target serum TSH levels have to be used to monitor L-T4 therapy 
in primary hypothyroidism (1). The target TSH in primary 
hypothyroidism “should be the normal range of a third generation 
TSH assay” or, if unavailable, should be 0.45–4.2 mU/l. However, 
according to the reference population of the National Health 
and Nutrition Examination Survey III, the normal values are 
0.45–5.90 mU/l in the 70- to 79-year-old and 0.33–7.50 mU/l in 
≥80-year-old patients. By contrast, the 2003 National Academy 
of Clinical Biochemistry Laboratory and Medicine Practice 
Guidelines suggest that the upper limit of normal range is 
2.5 mU/l (23).
A complete diagnostic work-up for failure of serum TSH to 
become normal is multidisciplinary, may require hospitalization 
and be expensive. The work-up includes several steps, whose 
number and order may vary in the individual patient (24). The 
initial steps involve confirmation of diagnosis and laboratory 
data, assessment of patient compliance, and control of the formu-
lations taken. Subsequent steps involve investigation of incorrect 
ingestion of L-T4, causes of malabsorption, including increased 
L-T4 turnover or excretion; if necessary, l-thyroxine absorption 
test is performed. A similar approach has been proposed by one 
of us elsewhere (5).
Here, we report two cases of undertreated hypothyroidism, 
causing increased requirement of daily doses of l-thyroxine, in 
patients with cirrhosis of the liver. In one patient, tablet L-T4 was 
replaced by oral liquid L-T4, which normalized serum TSH.
Report of the First Case
A 54-year-old man with hepatitis C virus-related liver cirrhosis 
had been diagnosed autoimmune hypothyroidism (atrophic 
variant of Hashimoto’s thyroiditis) approximately 8 years earlier, 
which was treated with 100 μg/day L-T4. Serum TSH had been 
consistently ≤3.4  mU/l, until symptomatology characterized 
by asthenia, weight loss, and yellowish staining of the sclera 
appeared. This led to the diagnosis of liver cirrhosis. Serum TSH 
increased to 9.3 mU/l so that L-T4 was progressively increased 
to 150 μg/day. However, serum TSH did not fall below 6.6 mU/l. 
When observed, the patient had scleral jaundice, bilateral 
gynecomastia and was treated with PPI (lansoprazole), a class of 
drugs that reduces the absorption of L-T4 by increasing gastric pH 
(3–8, 25–27). However, lansoprazole was taken discontinuously. 
Because of gynecomastia, serum testosterone, estradiol (E2), and 
prolactin (PRL) had been requested before our observation.
Results
Total testosterone was borderline low (300 ng/dl, reference range 
290–960), and E2 mildly elevated (53 pg/ml, reference range for 
men <40), as it was PRL (24 ng/ml, reference range for men <16). 
Knowing that thyroxine-binding globulin (TBG) is the estrogen-
upregulated and androgen-downregulated major thyroid hor-
mone plasma carrier (28–34) and that circulating TBG increases 
in liver diseases (28, 35–41), we complemented the PRL and sex 
hormone assays with TBG assay. We hypothesized that, similarly 
to the increased requirements of L-T4 replacement therapy dur-
ing gestation (a physiological hyperestrogenic state in which TBG 
is increased) (42, 43) but unlike the decreased requirements of 
L-T4 replacement therapy associated with hyperandrogenism 
(when serum TBG decreases) (34), elevation of serum TBG 
(and associated increased binding of L-T4 to it) might have 
contributed to undertreated hypothyroidism in our patient. 
Indeed, serum TBG was high (60 µg/ml; reference range 12–32), 
a level comparable to that of pregnant women. The patient was 
soon lost at follow-up. However, 5 years later, one of his relatives 
called over the telephone to have a second opinion concerning the 
combined L-T4 + L-T3 therapy. On that occasion, we learned that 
in our patient cirrhosis had been managed successfully by liver 
transplantation and that gynecomastia disappeared. Although 
he continued to take discontinuously PPI (6  h after L-T4), his 
latest serum TSH was 2.4 mU/l (reference range 0.27–4.2) under 
100 μg/day L-T4.
Report of the second Case
The second cirrhotic patient is a 64-year-old hypothyroid woman 
with the atrophic variant of Hashimoto’s thyroiditis under treat-
ment with tablet LT-4 over the last 10 years. She was euthyroid 
upon taking 150 μg/day L-T4, which was taken 30 min before 
breakfast. Twelve months after the last endocrinological control, 
she was diagnosed with hepatitis C virus-related cirrhosis. After 
7  months, laboratory tests showed subclinical hypothyroidism 
(TSH = 8.65 mU/l, FT4 = 9.5 pg/ml; Table 1), although her body 
weight had not undergone significant changes.
Results
Since we are aware of a better absorption profile of novel formula-
tions of L-T4 over the classic tablet formulation (see Discussion), 
we switched tablet L-T4 to oral liquid L-T4, without changing 
the daily dose. TSH levels became normal after about 60  days 
(3.0 mU/l), and both FT4 and FT3 levels increased from close to 
the lower normal limit to close to the mid-range value (12.3 and 
3.0 pg/ml) (Table 1). Accordingly, she felt better. To confirm that 
this improvement was not random, L-T4 was switched back to 
the tablet formulation at the same dosage. One month after this 
switch, serum TSH bounced back to abnormal levels, in parallel 
with a decline of both FT4 and FT3 levels (Table 1).
taBLe 1 | Thyroid parameters measured when patient no. 2 was receiving oral 
levothyroxine (L-T4) in the tablet formulation, after 2 months of L-T4 in the liquid 
formulation (in bold), and then after 1 month of return to the tablet formulation.a
L-t4 formulation tsH, mU/l Ft3, pg/ml Ft4, pg/ml
Tablet 8.65 2.7 9.5
Liquid 3.03 3.0 12.3
Tablet 6.37 2. 9 11. 8
aBecause body weight of this patient was stable (67–68 kg) over time, the daily dose 
of 150 μg/day was also stable when normalized for body weight, namely, 2.23 μg/kg 
b.w./day.
Reference ranges are 0.3–3.5 mU/l (TSH), 2.3–4.2 pg/ml (FT3), and 8–17 pg/ml (FT4). 
The tabulated hormone levels were measured at observation when the patient was 
under tablet L-T4, after 2 months from switch to oral liquid L-T4 and 1 month after 
switch back to tablet L-T4.
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DIsCUssIoN
Most patients with hepatitis C virus develop at least one extra-
hepatic manifestation, including autoimmune thyroid disease 
(44). Accordingly, hypothyroidism and thyroid autoimmunity 
are significantly more frequent in HCV patients with respect to 
controls (44).
The two patients reported here remind us that liver cirrhosis 
is one of the causes of undertreated hypothyroidism and asso-
ciated greater L-T4 requirement. The increased L-T4 require-
ment associated with liver cirrhosis could be due to defects 
in bile production and excretion. Indeed, bile is important to 
maximize the intestinal absorption of L-T4 (22). However, one 
additional mechanism for the increased dosage of L-T4 could 
be the same as that occurring in pregnancy or other conditions 
of hyperestrogenism (28, 29, 32, 33), namely, increased bind-
ing of L-T4 by the increased estrogen-driven serum levels of 
TBG, the major thyroid hormone plasma carrier, and failure 
to compensate for this increased binding. Elevation of serum 
E2 in cirrhosis and E2 normalization after liver transplanta-
tion was shown by other authors (41, 45). Congruent with 
our data on the second patient, an Italian study found that 
the increased L-T4 requirement occurring during gestation 
is significantly less frequent if hypothyroid pregnant women 
are supplemented with liquid L-T4 compared with tablet 
L-T4 (1/14 vs 7/17, P =  0.038) (46). An increased require-
ment of L-T4 is more likely to occur in pregnant women with 
no residual thyroid function (e.g., because of radioablation, 
thyroidectomy), compared with women with non-atrophic 
Hashimoto’s thyroiditis (42, 43). Non-iatrogenic conditions of 
absent functional thyroid tissue are thyroid agenesia or, like 
our patients, thyroid atrophia.
In the first cirrhotic patient described here, co-ingestion of 
one medication (a PPI) that is known to interfere with L-T4 
intestinal absorption (5–8) is unlikely to be the cause of under-
treated hypothyroidism. In the Sachmechi et  al. study (25), 37 
euthyroid patients who had received stable L-T4 replacement for 
at least 6 months and in whom lansoprazole therapy (the same 
PPI taken by our patient) was later initiated, serum TSH levels 
were measured before and at least 2  months after the PPI was 
started. Of the 37 patients, only 7 (19%) had post-PPI TSH levels 
>5 mU/l, requiring a mean increase of 20 μg/day L-T4 (+35%). 
By contrast, short-term (47, 48) and, presumably, discontinuous 
treatment with PPI (as in our patient) has no impact on L-T4 
intestinal absorption.
The second patient permits to add the chronic liver disease 
setting to the other settings (5, 6, 18, 26, 27, 49–63) in which 
novel formulations of L-T4, because of their more favorable 
pharmacokinetics profile, perform better than the classic tablet 
formulation in achieving target levels of TSH (64). From a 
gastroenterological perspective, settings of interest are the cor-
rection of the impaired tablet L-T4 absorption caused by food 
and beverages, anti-ulcerants (26, 27), esophageal dysmotility 
(15), gastritis (58, 59), enteral feeding (63), and bariatric sur-
gery (54, 55).
In sum, liver cirrhosis can cause undertreated primary 
hypothyroidism and associated increased L-T4 requirement. The 
L-T4 increased requirement is due to impaired bile secretion and 
increased serum TBG resulting in increased TBG-T4 binding. 
This augmented TBG-T4 binding cannot be compensated by 
increased free T4 levels originating from an increased thyroid 
gland secretion, if the patient has hyperestrogenism (which 
would raise serum TBG levels even more) and has no or minimal 
functioning thyroid tissue. A similar increased requirement of 
L-T4 is typically observed during gestation (a physiologic condi-
tion of elevated serum estrogens and serum TBG), especially 
in pregnant women with non functioning thyroid tissue, when 
serum TBG is elevated.
This study suggests that, further to the known situation in 
hypothyroid pregnant women, elevated serum levels of the 
major plasma carrier of thyroid hormones (TBG) increase the 
daily requirement of L-T4 also in hypothyroid men with an 
atrophied thyroid. Like in iatrogenic conditions of an entirely 
non-functional thyroid gland (i.e., radioablation and thyroidec-
tomy), the increased binding of L-T4 to circulating TBG cannot 
be compensated by an increased hormone output by the thyroid.
CoNCLUDING ReMaRKs
Our report highlights live cirrhosis as one cause of increased 
requirement for L-T4. Hepatic dysfunction may involve the rise in 
TBG concentrations, like in pregnancy. Our study is also the first 
showing that the L-T4 oral liquid formulation can solve the problem 
of the increased need of tablet L-T4 dose in liver cirrhosis because 
of better intestinal absorption.
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The patients gave written informed consent for the publication 
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